🔗 Share this article Recent Antimicrobials Recognized as a 'Turning Point' in Addressing Drug-Resistant Gonorrhoea The first new treatments for gonorrhoea in a generation are being described as a "significant breakthrough" in the battle against increasingly resistant strains of the bacteria, according to researchers. A Global Health Concern Gonorrhoea infections are on the rise around the world, with figures suggesting more than 82 million new cases each year. Particularly high rates are observed in the African continent and nations within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. Across England, cases have hit a historical peak, while rates across Europe in 2023 were three times higher compared to figures for 2014. “The authorization of new treatments for gonorrhoea is an important and timely advancement in the context of growing infection rates, the spread of superbugs and the very limited available drugs currently available.” Public health authorities are increasingly worried about the increase in antibiotic-resistant strains. The World Health Organization has classified it as a "critical concern". Ongoing monitoring revealed that resistance to standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024. Two New Drugs Receive Clearance Zoliflodacin, also known as Nuzolvence, was cleared by the American regulatory agency in recent days for combating gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Experts believe that specific application of this new drug will help delay the emergence of superbugs. Another new antibiotic, originating from the pharmaceutical company GSK, also received approval in concurrent days. This medication, which is employed against UTIs, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria. A Unique Approach to Creation Zoliflodacin was the result of a innovative non-profit model for drug creation. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to bring it to fruition. “This approval signifies a huge turning point in the therapy of highly resistant gonorrhoea, which until now has been staying ahead of our drug pipeline.” Clinical Trial Results and Global Access As per results released by a major medical journal, zoliflodacin cured over nine in ten of genital gonorrhoea infections. This places it at an similar efficacy with the existing first-line therapy, which combines two antibiotics. The trial enrolled hundreds of volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US. As part of the agreement of its collaboration, GARDP has the authority to license and sell the drug in numerous regions with limited resources. Doctors on the front lines have voiced optimism. Access to a single-dose, oral treatment such as this is seen as a "game-changer" for gonorrhoea control. This is considered essential to reduce the burden of the infection for individuals and to prevent the spread of untreatable gonorrhoea worldwide.